Tayná Evily de Lima

Tayná Evily de Lima

Auto-generated profile, based on publicly available information

Tayná Evily de Lima

Fundação Oswaldo Cruz, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Clinics
Verified
Journal Article
Open access
LSLaís Teodoro da Silva
Laís Teodoro da Silva
MOMarina Mazzilli Ortega
Marina Mazzilli Ortega
BTBruna Tiyo
Bruna Tiyo
IVIsabelle F.T. Viana
Isabelle F.T. Viana
TLTayná Evily de Lima
Tayná Evily de Lima
TOTelma Miyuki Oshiro
Telma Miyuki Oshiro
In this preliminary study we investigated cellular and humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens in blood samples from 14 recovered coronavirus disease 2019 (COVID-19) patients and compared them ...

1 January 2024 in Anais da Academia Brasileira de Ciências
Verified
Journal Article
Open access
PDF file
TLTayná E. Lima
Tayná E. Lima
MFMatheus V.F. Ferraz
Matheus V.F. Ferraz
CBCARLOS ANTUNES BRITO
CARLOS ANTUNES BRITO
PXPamella B. Ximenes
Pamella B. Ximenes
CMCarolline Araujo Mariz
Carolline Araujo Mariz
RLRoberto Lins
Roberto Lins
The need for the identification of risk factors associated to COVID-19 disease severity remains urgent. Patients’ care and resource allocation can be potentially different and are defined based on the current classification of disease severity. This classification is based on the analysis of clinical parameters and routine blood tests, which are not standardized across the globe. Some laboratory test alterations have been associated to COVID-19 severity, although these data are conflicting partly due to the different methodologies used across different studies. This study aimed to construct and validate a disease severity prediction model using machine learning (ML). Seventy-two patients admitted to a Brazilian hospital and diagnosed with COVID-19 through RT-PCR and/or ELISA, and with varying degrees of disease severity, were included in the study. Their electronic medical records and the results from daily blood tests were used to develop a ML model to predict disease severity. Using the above data set, a combination of five laboratorial biomarkers was identified as accurate predictors of COVID-19 severe disease with a ROC-AUC of 0.80 ​±​ 0.13. Those biomarkers included prothrombin activity, ferritin, serum iron, ATTP and monocytes. The application of the devised ML model may help rationalize clinical decision and care.